Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01423591|
Recruitment Status : Unknown
Verified August 2011 by Dr. Vicente Rodri-guez Valverde, Hospital Universitario Marqués de Valdecilla.
Recruitment status was: Active, not recruiting
First Posted : August 26, 2011
Last Update Posted : August 26, 2011
Rheumatic Polymyalgia(PMR) is a relatively common chronic inflammatory disorder of unknown origin which predominantly develops in elderly subjects and presents with severe pain and stiffness in the neck, shoulder and pelvic girdles, along with increased acute phase reactants. Systemic manifestations such as fever, anorexia and weight loss are characteristic signatures of PMR.
Corticosteroids (CS) constitute the standard treatment of PMR. Although in most patients the symptoms of the disease disappear after one or two years of treatment, a proportion of patients remain CS-dependent with the subsequent CS toxicity. Open label studies have suggested that tumour necrosis factor (TNF) antagonists lead to sustained improvement and CS sparing effect in patients with refractory PMR.
The investigators conducted a randomised, double-blind, placebo controlled trial with infliximab in CS-dependent patients with PMR. Patients with CS-dependent PMR (defined as requiring ≥ 5 mg/day after at least 2 years of treatment to maintain remission or ≥ 7.5 mg/day after at least 6 months) were randomly assigned to receive Infliximab (5 mg/kg i.v) at 0, 2, 6, 14 and 22 weeks (n = 12) or placebo (n = 11) together with CS that were reduced according to a predefined schedule. The primary outcome was the proportion of responder patients -defined as individuals with both complete clinical and analytical remission without receiving CS for at least three months- at 24 weeks. Secondary outcomes were cumulative CS doses and adverse events proportion.
|Condition or disease||Intervention/treatment||Phase|
|Polymyalgia Rheumatica||Drug: infliximab Drug: inactive powder||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica: a Double Blind Placebo Controlled Trial|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||September 2010|
|Estimated Study Completion Date :||December 2011|
Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
Other Name: Remicade, anti-TNF monoclonal Therapy
|Placebo Comparator: inactive powder||
Drug: inactive powder
Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
Other Name: placebo
- Proportion of responders(complete remission without corticosteroids) [ Time Frame: at 24 weeks ]
- Proportion of responders [ Time Frame: at 48 weeks ]
- Time to response [ Time Frame: 48 weeks ]
- Number of relapses / recurrences [ Time Frame: 48 weeks ]
- Response duration [ Time Frame: 48 weeks ]
- Cumulative dose and side effects of steroids [ Time Frame: at 24 and 48 weeks ]
- Number of patients that should be re-treated with infliximab [ Time Frame: 48 weeks ]
- Side effects of Infliximab in this patient population [ Time Frame: 48 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01423591
|Reumatology division, Hospital Universitario Marques de Valdecilla|
|Santander, Cantabria, Spain, 39008|
|Study Director:||Víctor M Martínez-Taboada,, Md, PhD||Servicio de Reumatología, Hospital Universitario Marques de Valdecilla|
|Principal Investigator:||Vicente Rodriguez-Valverde, MD, PhD||Servicio de Reumatología, Hospital Universitario Marques de Valdecilla|